{"id":2585,"date":"2018-03-13T15:04:32","date_gmt":"2018-03-13T09:34:32","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2585"},"modified":"2023-06-14T16:48:19","modified_gmt":"2023-06-14T11:18:19","slug":"notizia-pharma-news-2","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news-2","title":{"rendered":"Notizia"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Anthera\u2019s Sollpura flops after phase 3 \u00a0<\/strong><\/p>\n<p style=\"text-align: justify;\">Anthera cut free it\u2019s flopped late-arrange Lilly castoff Sollpura (liprotamase), and now looks for those feared &#8220;key choices&#8221;. Sollpura was out-licensed by Lilly in 2014, and the written work had all the attributes of its failure, back in December 2016 when it posted the information from its stage 3 Solution test for cystic fibrosis patients which revealed enzyme deficiency that obstructs digestion.<\/p>\n<p style=\"text-align: justify;\"><strong>Sanofi finally gave up on Alnylam\u2019s rare genetic disease drug<\/strong><\/p>\n<p style=\"text-align: justify;\">Sanofi has walked out of Alnylam\u2019s primary hyperoxaluria type 1 (PH1) drug <strong>Lumasiran<\/strong>, a rare genetic disease drug after assessing the phase 1\/2 data Alnylam presented late last year. This has given Alnylam control of a phase 3-ready rare disease drug with an FDA breakthrough therapy designation. Sanofi Genzyme was granted the option to pick up rights outside of North America and Western Europe in 2014.<\/p>\n<p style=\"text-align: justify;\"><strong>Australian scientist predicting immuno-oncology accomplishment in lung cancer<\/strong><\/p>\n<p style=\"text-align: justify;\">Scientists in Australia have predicted that about 20% of adenocarcinomas may react to immune-oncology treatments as they get marked in KEAP1\/NRF2 pathway. This may lead to the treatment of lung cancer which commonly occurs in women &amp; young people. They published their\u00a0findings\u00a0in the journal Cell Metabolism which says that these tumors leave in the blood which might be utilized to distinguish patients react to drugs that restrain the safe checkpoints PD-1 and CTLA-4. The marker is additionally left by adenocarcinomas with variations from the normal in another pathway called PI3K.<\/p>\n<p style=\"text-align: justify;\"><strong>Bischofberger withdraws from Gilead\u2019s R&amp;D lead <\/strong><\/p>\n<p style=\"text-align: justify;\">Gilead to get John McHutchison as the new CSO this April as Norbert Bischofberger withdraws from EVP of R&amp;D and chief scientific officer. Andrew Cheng EVP of clinical research and ops, will become\u00a0Gilead\u2019s CMO. They will be reporting to John Milligan, Gilead\u2019s president and chief.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Anthera\u2019s Sollpura flops after phase 3 \u00a0 Anthera cut free it\u2019s flopped late-arrange Lilly castoff Sollpura (liprotamase), and now looks for those feared &#8220;key choices&#8221;. Sollpura was out-licensed by Lilly in 2014, and the written work had all the attributes of its failure, back in December 2016 when it posted the information from its stage [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2303,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":1,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1507,1504,1509,204,794,1508,1506,730,1261,712,1119,533,1505],"industry":[17225],"therapeutic_areas":[17238,17228,17234],"class_list":["post-2585","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-alnylam","tag-anthera","tag-bischofberger","tag-delveinsight","tag-gilead","tag-keap1nrf2","tag-liprotamase","tag-notizia","tag-pharma-consulting","tag-pharma-industry","tag-pharmaceutical","tag-sanofi","tag-sollpura","industry-pharmaceutical","therapeutic_areas-genetic-disorders","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia- Latest Pharmaceutical Industry News (Delveinsight)<\/title>\n<meta name=\"description\" content=\"Anthera cut free it\u2019s flopped late-arrange Lilly castoff Sollpura (liprotamase), and now looks for those feared &quot;key choices&quot;.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news-2\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia- Latest Pharmaceutical Industry News (Delveinsight)\" \/>\n<meta property=\"og:description\" content=\"Anthera cut free it\u2019s flopped late-arrange Lilly castoff Sollpura (liprotamase), and now looks for those feared &quot;key choices&quot;.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news-2\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-03-13T09:34:32+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T11:18:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif\" \/>\n\t<meta property=\"og:image:width\" content=\"750\" \/>\n\t<meta property=\"og:image:height\" content=\"315\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/gif\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia- Latest Pharmaceutical Industry News (Delveinsight)","description":"Anthera cut free it\u2019s flopped late-arrange Lilly castoff Sollpura (liprotamase), and now looks for those feared \"key choices\".","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news-2","og_locale":"en_US","og_type":"article","og_title":"Notizia- Latest Pharmaceutical Industry News (Delveinsight)","og_description":"Anthera cut free it\u2019s flopped late-arrange Lilly castoff Sollpura (liprotamase), and now looks for those feared \"key choices\".","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news-2","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-03-13T09:34:32+00:00","article_modified_time":"2023-06-14T11:18:19+00:00","og_image":[{"width":750,"height":315,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif","type":"image\/gif"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news-2","url":"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news-2","name":"Notizia- Latest Pharmaceutical Industry News (Delveinsight)","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news-2#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news-2#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif","datePublished":"2018-03-13T09:34:32+00:00","dateModified":"2023-06-14T11:18:19+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Anthera cut free it\u2019s flopped late-arrange Lilly castoff Sollpura (liprotamase), and now looks for those feared \"key choices\".","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news-2"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-pharma-news-2#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315.gif","width":750,"height":315,"caption":"Notizia"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/09\/09021345\/news-750x315-300x126.gif","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alnylam<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Anthera<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bischofberger<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gilead<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">KEAP1\/NRF2<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">liprotamase<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharma Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharmaceutical<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sanofi<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Sollpura<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alnylam<\/span>","<span class=\"advgb-post-tax-term\">Anthera<\/span>","<span class=\"advgb-post-tax-term\">Bischofberger<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Gilead<\/span>","<span class=\"advgb-post-tax-term\">KEAP1\/NRF2<\/span>","<span class=\"advgb-post-tax-term\">liprotamase<\/span>","<span class=\"advgb-post-tax-term\">Notizia<\/span>","<span class=\"advgb-post-tax-term\">pharma consulting<\/span>","<span class=\"advgb-post-tax-term\">Pharma Industry<\/span>","<span class=\"advgb-post-tax-term\">pharmaceutical<\/span>","<span class=\"advgb-post-tax-term\">Sanofi<\/span>","<span class=\"advgb-post-tax-term\">Sollpura<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Mar 13, 2018","modified":"Updated on Jun 14, 2023"},"absolute_dates_time":{"created":"Posted on Mar 13, 2018 3:04 pm","modified":"Updated on Jun 14, 2023 4:48 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2585","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2585"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2585\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2303"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2585"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2585"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2585"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2585"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2585"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}